Efficacy and safety of levetiracetam for outpatient alcohol detoxification

Pharmacopsychiatry

Volumn 43, Issue 5, 2010, Pages 184-189

  Muller C A ^a   Schafer M ^b   Schneider, S ^a   Heimann, H M ^a   Hinzpeter, A ^a   Volkmar, K ^a   Forg A ^a   Heinz, A ^a   Hein, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; ETIRACETAM; ANTICONVULSIVE AGENT; PIRACETAM;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; DELIRIUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH PROGRAM; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; PRURITUS; RELAPSE; RISK ASSESSMENT; SEDATION; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME; VERTIGO; WITHDRAWAL SYNDROME; ADOLESCENT; ADULT; AGED; ALCOHOL ABSTINENCE; AMBULATORY CARE; ANALOGS AND DERIVATIVES; DRINKING BEHAVIOR; MIDDLE AGED; PSYCHOLOGY; PSYCHOTHERAPY; RECURRENT DISEASE; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALCOHOL DRINKING; ALCOHOLISM; AMBULATORY CARE; ANTICONVULSANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; PSYCHOTHERAPY; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TEMPERANCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954876058     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1249098     Document Type: Article

References (42)

1. th ed. American Psychiatric Association, Washington, DC 1994
2. Bennett B, Lamberty Y, Bizot JC, et al. Levetiracetam prevents signs of alcohol withdrawal in mice New Research Program and Abstracts of the 156th Annual Meeting of the American Psychiatric Association; May 21, 2003; San Francisco (Abstract NR689). 2003 58
3. Bottlender M, Soyka M. Efficacy of an intensive outpatient rehabilitation program in alcoholism: predictors of outcome 6 months after treatment. Eur Addict Res 2005 11 132-137
4. Bottlender M, Soyka M. Outpatient alcoholism treatment: predictors of outcome after 3 years. Drug Alcohol Depend 2005 80 83-89
5. Burtscheidt W, Schwarz R, Wolwer W, et al. [Outpatient behavioural treatment in alcoholism: alcohol consumption and sociodemographic factors]. Fortschr Neurol Psychiatr 2001 69 526-531
6. Chabolla DR, Harnois DM, Meschia JF. Levetiracetam monotherapy for liver transplant patients with seizures. Transplant Proc 2003 35 1480-1481
7. Collins MN, Burns T, van den Berk PA, et al. A structured programme for out-patient alcohol detoxification. Br J Psychiatry 1990 156 871-874
8. Cramer JA, De Rue K, Devinsky O, et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003 4 124-132
9. De Witte P, Pinto E, Ansseau M, et al. Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev 2003 27 189-197
10. Franz M, Dlabal H, Kunz S, et al. Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study. Eur Arch Psychiatry Clin Neurosci 2001 251 185-192
11. Fuks B, Gillard M, Michel P, et al. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur J Pharmacol 2003 478 11-19
12. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006 536 102-108
13. Gower AJ, Noyer M, Verloes R, et al. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992 222 193-203
14. Heinz A, Dufeu P, Kuhn S, et al. Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients. Arch Gen Psychiatry 1996 53 1123-1128
15. Klijnsma MP, Cameron ML, Burns TP, et al. Out-patient alcohol detoxification outcome after 2 months. Alcohol Alcohol 1995 30 669-673
16. Kosten TR, OConnor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003 348 1786-1795
17. Krebs M, Leopold K, Richter C, et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol 2006 26 347-349 (Pubitemid 43804637)
18. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004 291 605-614
19. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998 284 474-479
20. Lucht M, Kuehn KU, Armbruster J, et al. Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam. Alcohol Alcohol 2003 38 168-175
21. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004 101 9861-9866
22. Malcolm R, Myrick H, Brady KT, et al. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 2001 10 (Suppl) 16-23
23. Margineanu DG, Klitgaard H. Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. Eur J Pharmacol 2003 466 255-261
24. Mariani JJ, Levin FR. Pharmacotherapy for alcohol-related disorders: what clinicians should know. Harv Rev Psychiatry 2004 12 351-366
25. Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 2004 164 1405-1412
26. Mazza M, Martini A, Scoppetta M, et al. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008 32 539-543
27. Mula M, Sander JW. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav 2007 11 130-132
28. Mundle G, Brugel R, Urbaniak H, et al. Short- and medium-term outcome of outpatient treatment of alcohol dependent patients. A 6-, 18- and 36-month follow-up. Fortschr Neurol Psychiatr 2001 69 374-378
29. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995 286 137-146
30. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000 85 77-85
31. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004 43 707-724
32. Paul F, Meencke HJ. Levetiracetam in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2004 45 559-560
33. Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy 1996 16 49-57
34. Soyka M, Morhart-Klute V, Horak M. A combination of carbamazepine/ tiapride in outpatient alcohol detoxification. Results from an open clinical study. Eur Arch Psychiatry Clin Neurosci 2002 252 197-200
35. Soyka M, Schmidt F, Schmidt P. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence. Pharmacopsychiatry 2006 39 30-34
36. Soyka M, Schmidt P. Outpatient alcoholism treatment 24-month outcome and predictors of outcome. Subst Abuse Treat Prev Policy 2009 4 15
37. Stahl SM. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry 2004 65 1162-1163
38. Webb M, Unwin A. The outcome of outpatient withdrawal from alcohol. Br J Addict 1988 83 929-934
39. Wetterling T, Kanitz RD, Besters B, et al. A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale). Alcohol Alcohol 1997 32 753-760
40. WHO. Internationale Klassifikation psychischer Störungen ICD-10 Kapitel V (F) Forschungskriterien. Dilling H, Mombour W, Schmidt MH, Schulte-Warkwort E, eds. Huber, Bern 1994
41. Wiseman EJ, Henderson KL, Briggs MJ. Individualized treatment for outpatients withdrawing from alcohol. J Clin Psychiatry 1998 59 289-293
42. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005 15 357-376